PMID- 11519142
OWN - NLM
STAT- MEDLINE
DCOM- 20011018
LR  - 20110727
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 59
IP  - 8
DP  - 2001 Aug
TI  - [Function of monoamine neurotransmitter transporters].
PG  - 1457-64
AB  - Monoamine transporters include plasma membrane and vesicular monoamine 
      transporters(VMAT). The former selectively and Na+/Cl(-)-dependently transport 
      dopamine, noradrenaline and serotonin into the cytoplasma, and the latter 
      non-selectively carries monoamine into the vesicle. These transporters are 
      composed of amino acid groups containing 12 folds more transmembrane components. 
      Cytoplasmic transporters are a target site of certain drugs. Antiepileptic drugs 
      such as SSRI and tricyclic antidepressants bind with serotonin transporter(SERT), 
      noradrenaline transporter(NET) and/or dopamine transporters(DAT) to inhibit 
      transport of monoamines into the cytoplasma, thereby increasing monoamine levels 
      within the synaptic cleft. However, amphetamine, known to induce drug dependence, 
      is transported by DAT and inhibit VMAT to induce reverse-transport of monoamines 
      into the synaptic area, thereby producing psychiatric and behavioral alterations. 
      Thus, monoamine transporters are target sites of drugs, and functional changes in 
      the transporters may be involved in the pathogenesis of affective diseases, 
      schizophrenia and/or personality disorders including neurogenerative diseases 
      such as Parkinson's disease.
FAU - Sasa, M
AU  - Sasa M
AD  - Department of Pharmacology, Hiroshima University School of Medicine.
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
RN  - 0 (Biogenic Monoamines)
RN  - 0 (Carrier Proteins)
RN  - 0 (Central Nervous System Agents)
RN  - 0 (Dopamine Plasma Membrane Transport Proteins)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Membrane Transport Proteins)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (Neuropeptides)
RN  - 0 (Norepinephrine Plasma Membrane Transport Proteins)
RN  - 0 (SLC6A2 protein, human)
RN  - 0 (SLC6A3 protein, human)
RN  - 0 (SLC6A4 protein, human)
RN  - 0 (Serotonin Plasma Membrane Transport Proteins)
RN  - 0 (Symporters)
RN  - 0 (Vesicular Biogenic Amine Transport Proteins)
SB  - IM
MH  - Animals
MH  - Binding Sites
MH  - Biogenic Monoamines/metabolism
MH  - Carrier Proteins/*physiology
MH  - Central Nervous System Agents/metabolism/pharmacology
MH  - Cytoplasm/metabolism
MH  - Dopamine Plasma Membrane Transport Proteins
MH  - Humans
MH  - Membrane Glycoproteins/*physiology
MH  - *Membrane Transport Proteins
MH  - Mental Disorders/etiology
MH  - *Nerve Tissue Proteins
MH  - Neurodegenerative Diseases/etiology
MH  - *Neuropeptides
MH  - Norepinephrine Plasma Membrane Transport Proteins
MH  - Serotonin Plasma Membrane Transport Proteins
MH  - *Symporters
MH  - Vesicular Biogenic Amine Transport Proteins
RF  - 20
EDAT- 2001/08/25 10:00
MHDA- 2001/10/19 10:01
CRDT- 2001/08/25 10:00
PHST- 2001/08/25 10:00 [pubmed]
PHST- 2001/10/19 10:01 [medline]
PHST- 2001/08/25 10:00 [entrez]
PST - ppublish
SO  - Nihon Rinsho. 2001 Aug;59(8):1457-64.